Vivimed Labs Ltd (VIVIMEDLAB)

Healthcare · Pharmaceuticals · NSE · Updated 1 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹6.93

🎯 Key Takeaways

Vivimed Labs Ltd is currently in a distressed restructuring phase following the initiation of Corporate Insolvency Resolution Process (CIRP) by NCLT in April 2026. The company has been grappling with persistent losses, negative operating margins, and declining revenue trends over recent quarters.
Revenue declined 25% QoQ to ₹12 in Q4FY26.
⚠️ Ongoing Corporate Insolvency Resolution Process (CIRP) with high uncertainty around resolution plan approval and creditor recovery outcomes.

Market Cap

₹57

P/B Ratio

-1.63

ROE

501.8%

ROCE

-50.5%

Debt/Equity

-10.70

Promoter

7.6%

✨ Ask AI About VIVIMEDLAB 📊 Interactive Charts

📖 The Story

Vivimed Labs Ltd is currently in a distressed restructuring phase following the initiation of Corporate Insolvency Resolution Process (CIRP) by NCLT in April 2026. The company has been grappling with persistent losses, negative operating margins, and declining revenue trends over recent quarters. Management is actively engaged in creditor-led resolution efforts, with recent filings indicating procedural progress toward a potential restructuring plan. The absence of transparent financial disclosures and ongoing regulatory complexities underscore the high uncertainty surrounding its near-term viability.

📰 What's Happening

The most significant development is the scheduled sixth Committee of Creditors meeting on August 18, 2026, under the ongoing CIRP initiated by NCLT on April 15, 2026. This follows a Form G filing on June 17, 2026, which outlined procedural timelines for expression of interest and resolution plan submissions, including key deadlines in late June and July 2026. The company has also been navigating compliance issues, including a delayed financial filing due to a technical scanning error and missing SEBI MD/CEO signature in May 2026. Additionally, a voluntary delisting proposal was announced in July 2026 via postal ballot, reflecting management's focus on strategic alternatives amid insolvency proceedings. These events highlight a company in active restructuring mode, with limited operational transparency and increasing creditor involvement.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	21	21	16	12
Operating Profit	-5	-6	-16	-152
OPM %	-24.8%	-28.4%	-97.3%	-1264.9%
Net Profit	-5	-7	-17	-147
EPS	₹-0.66	₹-0.88	₹-2.00	₹-17.24

Vivimed Labs has exhibited a clear downward financial trajectory over the past four quarters, with revenue declining from ₹21 Cr in Q3FY25 to ₹12 Cr in Mar 2026, accompanied by widening net losses. Operating performance remains severely negative, with operating profit margins deteriorating to -1264.9% in Q4FY25 (Mar 2026), despite marginal improvements in cost control reflected in less negative OPM trends. Net loss per share has also worsened, rising from ₹-0.66 in Jun 2025 to ₹-17.24 in Mar 2026. These trends suggest deteriorating fundamentals, though the company has not disclosed detailed financial results in recent filings, instead focusing on procedural and regulatory updates. The lack of audited financial transparency further complicates assessment of underlying performance.

🔮 Management Outlook & What's Next

Management has not provided explicit forward-looking guidance on business recovery, revenue growth, or path to profitability in the available filings. Instead, commentary has centered on regulatory compliance, procedural delays in financial reporting, and participation in insolvency processes. Key announcements include the postponement of board meetings due to technical and submission issues, as well as the proposal for voluntary delisting via postal ballot. The absence of strategic growth commentary or operational turnaround plans indicates that management is currently prioritizing legal and administrative resolution over business development or financial guidance.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	17	17	17	17
Reserves	-42	-52	-65	-227
Borrowings	376	376	384	397
Total Liabilities	943	921	924	753
Fixed Assets	258	408	245	237
Investments	169	169	168	181
Total Assets	943	921	924	753

The balance sheet reflects a highly leveraged and capital-constrained structure, with total borrowings of ₹397 Cr against a negative equity position of ₹-227 Cr in reserves as of Mar 2026. Despite asset growth to ₹753 Cr, equity has remained stagnant at ₹17 Cr, suggesting that operations are being funded through debt and reserves depletion. The consistent rise in borrowings over time, coupled with persistent losses, raises concerns about solvency and long-term financial sustainability. Capital allocation appears reactive rather than strategic, with no evidence of deleveraging or reinvestment in growth areas.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2025
Operating	-2
Investing	-5
Financing	+5
Net Cash Flow	-1

👥 Shareholding Pattern

Category	Q1FY26	Q2FY26	Q3FY26	Q4FY26
Promoters	7.8%	7.8%	7.8%	7.6%
FII	1.6%	1.6%	1.6%	1.6%
DII	0.0%	0.0%	0.0%	0.0%
Public	65.2%	65.2%	65.1%	68.8%
# Shareholders	48,928	48,925	49,221	47,492

Promoter holding remains low and stable at approximately 7.57% over recent quarters, with no signs of accumulation or reduction. Institutional ownership is negligible, with FII holding flat at 1.64% and DII at 0% across all quarters. Public shareholding has slightly increased to 68.75% in Q4FY26 from 65.06% in Q3FY26, possibly due to retail buying or index rebalancing. The lack of institutional interest and minimal promoter stake suggest limited confidence from key investors. No pledging or significant shareholding changes are reported, but the low liquidity and dispersed ownership may amplify volatility during restructuring.

⚖️ Peer Comparison — Pharmaceuticals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
SUNPHARMA	4.69 L Cr	38.8	18.7%	14.6%	0.05
DIVISLAB	2.45 L Cr	83.9	23.0%	17.4%	0.00
TORNTPHARM	1.89 L Cr	79.4	15.1%	25.7%	1.76
ZYDUSLIFE	1.16 L Cr	25.9	16.8%	16.6%	0.43
CIPLA	1.14 L Cr	33.9	13.2%	9.8%	0.01
LAURUSLABS	1.03 L Cr	94.1	20.8%	20.6%	0.45
LUPIN	99,585	17.6	27.9%	24.7%	0.26
MANKIND	99,078	48.5	13.9%	12.7%	0.38
DRREDDY	97,240	30.1	10.1%	8.4%	0.17
AUROPHARMA	97,239	26.4	12.8%	9.8%	0.20

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM ZYDUSLIFE CIPLA

⚠️ Risk Factors

1. Ongoing Corporate Insolvency Resolution Process (CIRP) with high uncertainty around resolution plan approval and creditor recovery outcomes. 2. Persistent financial losses, negative cash flows, and deteriorating operating margins with no visible path to profitability. 3. Lack of transparent and timely financial disclosures, including corrupted filings and delayed reporting, undermining investor confidence. 4. Low institutional interest and minimal promoter stake, contributing to share price volatility and limited market depth. These factors collectively create a high-risk environment with potential for significant capital impairment.

📋 Recent Filings

🧠 Analyst's Read

Vivimed Labs is currently in a critical phase of restructuring with limited visibility into financial recovery or operational revival. Investors should monitor developments from the August 18, 2026, Committee of Creditors meeting for clarity on the resolution path, as well as any future financial disclosures post-CIRP. The company's ability to stabilize operations, restore creditor trust, and return to profitability will be key determinants of stakeholder value. Until then, the risk-reward profile remains highly speculative and constrained by procedural and financial headwinds.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on VIVIMEDLAB

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-01.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when VIVIMEDLAB files new disclosures

Track VIVIMEDLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track VIVIMEDLAB — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd